Stock Market & Financial Investment News

News Breaks March 14, 2013 06:54 EDT LLY, RHHBY FDA wants to relax criteria for Alzheimer's drug approval, NY Times says The FDA intends to make it easier for companies to obtain approval of new treatments for Alzheimer’s disease, according to The New York Times. Under the agency's proposal, drugs could be approved if they improve peoples' performance on cognitive tests even before symptoms become apparent, and companies would not have to demonstrate that their drugs improve patients' functioning, the newspaper explained. Currently companies must show that their drugs improve patients' day to day functioning in order to obtain FDA approval of treatments, The Times added. Reference Link News For LLY;RHHBY From The Last 14 Days Check below for free stories on LLY;RHHBY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 23, 2013 15:19 EDT RHHBY FDA announces approval of Roche diabetes test Subscribe for More Information May 22, 2013 10:33 EDT RHHBY Bristol-Myers jumps after Citi ups rating on cancer potential Subscribe for More Information 10:00 EDT RHHBY On The Fly: Analyst Upgrade Summary Subscribe for More Information 06:02 EDT RHHBY Roche upgraded to Buy from Neutral at Citigroup Subscribe for More Information May 21, 2013 20:03 EDT RHHBY Roche, Sigma-Aldrich teamed for Life bid, Reuters says Subscribe for More Information 07:24 EDT LLY Global Health Care to host a conference Subscribe for More Information May 20, 2013 17:26 EDT RHHBY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 17:20 EDT RHHBY Regeneron,, Bayer, Genentech resolve certain patent disputes Subscribe for More Information May 16, 2013 08:55 EDT LLY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 15, 2013 15:59 EDT RHHBY Roche exploring sale of blood glucose meters unit, Reuters says Subscribe for More Information 12:13 EDT RHHBY Roche management to meet with Jefferies Meeting to be held in London on May 17 hosted by Jefferies. 11:38 EDT RHHBY Roche says FDA approves Tarceva tablets for specific lung cancer situation Subscribe for More Information May 14, 2013 16:55 EDT RHHBY FDA approves Roche's cobas EGFR mutation test with Tarceva Subscribe for More Information 09:09 EDT LLY Eli Lilly announces CEO John Lechleiter recovering from surgery Subscribe for More Information 07:24 EDT LLY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 08:55 EDT RHHBY Biosimiliar drug bill to be taken up in Senate, LA Times reports Subscribe for More Information 07:30 EDT RHHBY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 15:59 EDT RHHBY Roche spokesman reiterates that Illumina is "off the table," Bloomberg reports Subscribe for More Information 11:48 EDT RHHBY, LLY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 08:02 EDT LLY Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. Sign up for a free trial to see the rest of the stories you've been missing.